Select Equity Group’s Integra LifeSciences IART Stock Holding History

Select Equity Group’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-319,871	Closed	-$18.4M	–	172
2023 Q1	$18.4M	Sell	319,871 -521,922	-62%	-$29.4M	0.07%	101
2022 Q4	$47.2M	Buy	+841,793	New	+$42.8M	0.18%	82

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Select Equity Group's IART Position: Q2 2023 in Review

Select Equity Group sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 319,871 shares — an estimated $18.4M sold.

Select Equity Group first reported a position in IART in Q4 2022 and held it in 2 quarters. The position peaked at $47.2M in Q4 2022. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

Select Equity Group reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
Select Equity Group sold 319,871 Integra LifeSciences shares in Q2 2023, an estimated $18.4M.
Select Equity Group first reported a position in Integra LifeSciences in Q4 2022 and held it in 2 quarters.
Select Equity Group's Integra LifeSciences position peaked at $47.2M in Q4 2022.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on Select Equity Group's 13F filing for Q2 2023, filed 14 Aug 2023.